IL-CHEETAH-DIGITAL
10.11.2020 18:02:08 CET | Business Wire | Press release
Cheetah Digital , a cross-channel customer engagement solution provider for the modern marketer, today announces Cheetah Personalization at Signals 2020 . This next-generation personalization solution is the newest addition to the Cheetah Customer Engagement Suite that includes the Cheetah Engagement Data Platform, Experiences, Messaging, and Loyalty. Cheetah Personalization helps marketers orchestrate real-time interactions across all channels and touchpoints.
To remain competitive in today’s signal-saturated world, marketers need to deliver relevant, personalized content throughout the customer journey. Ninety-one percent of consumers are more likely to shop with brands who recognize, remember, and provide relevant offers and recommendations. Furthermore, real-time offers and content can be 10 times more effective than traditional outbound marketing campaigns.
“Personalization is in the fabric of everything marketers do. But as a strategy, technology and a market, personalization is ripe for reinvention,” said Sameer Kazi, CEO at Cheetah Digital. “We wanted to create a technology blueprint for brands to achieve personalization success. With Cheetah Digital, the next-generation of personalization is here. It’s the way forward for marketers to achieve their personalization, and ultimately business, goals.”
Organizations need technology to orchestrate each aspect of personalization, from data to distribution, in order to unlock the full power of personalization. With cookies and third-party data no longer being viable options for marketers, first and zero-party data are at the core of next-generation personalization.
Cheetah Personalization leverages analytics and machine learning to evaluate every customer on an individual level to derive the right content, offer, channel and sequence for a customer journey. The new solution includes delivering the next-best experience, next-best journey and next-best offers. These capabilities are enabled by three key product offerings:
- Cheetah Real-Time Personalization: Allows you to engage with customers in real-time with targeted experiences by capturing streaming data on web and mobile.
- Cheetah Journey Designer: Gives marketers the power to build, manage and optimize multi-step, multi-stage customer journeys at scale.
- Cheetah Intelligent Offers : Applies marketing insights and machine learning to optimize experiences and generate the next best offer and next best action.
“Personalization is one of the most critical themes for our customers and organization,” said Bill Ingram, Chief Product Officer at Cheetah Digital. “It’s not about guesswork, cookies or third-party data. The next generation of personalization is about providing a value exchange for consumers in the “moment” when you have them on your mobile app, on your site, in your store, where you can provide them something that will generate trust and affinity with the brand. With the data foundation of the Engagement Data Platform, we are well equipped to deliver a first class, next-generation personalization solution.”
“We were tasked with making better use of our data for more effective personalization for our guests in the face of a rapidly changing landscape,” said Katie Rhine, Corporate Marketing Manager at SeaWorld. “With Cheetah Digital’s solution, we were able to leverage zero-party data from email and deliver a more relevant and personalized experience for our guests. Now, we can personalize experiences at scale and create loyal customers across all our locations.”
This follows Cheetah Digital’s recent recognition in the MarTech Breakthrough Awards, where it was named Best Enterprise CRM Solution . To learn more about these updates and the new Cheetah Personalization solution, visit cheetahdigital.com/solutions/cheetah-personalization .
About Cheetah Digital
Cheetah Digital is a cross-channel customer engagement solution provider for the modern marketer. The Cheetah Digital Customer Engagement Suite enables marketers to create personalized experiences, cross-channel messaging, and loyalty strategies, underpinned by an engagement data platform that can scale to meet the changing demands of today's consumer. Many of the world’s best brands, including Hilton, Neiman Marcus, Walgreens, and Williams-Sonoma trust Cheetah Digital to help them drive revenue, build lasting customer relationships, and deliver a unique value exchange throughout the customer lifecycle. To learn more, visit www.cheetahdigital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005797/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom